Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Extends Commitment to InforSense Technology

NEW YORK, Jan. 16 (GenomeWeb News) - AstraZeneca will extend its use of InforSense's informatics platform, InforSense said today.

 

InforSense, based in London, will build a new Open Discovery Workflow platform at AstraZeneca's research site in Molndal, Sweden, which will be accessed by researchers at several AstraZeneca sites.

 

AstraZeneca has been using InforSense technology since 2001.

 

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.